1. Home
  2. IOTR vs NRXP Comparison

IOTR vs NRXP Comparison

Compare IOTR & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOTR
  • NRXP
  • Stock Information
  • Founded
  • IOTR 2019
  • NRXP 2015
  • Country
  • IOTR Singapore
  • NRXP United States
  • Employees
  • IOTR N/A
  • NRXP N/A
  • Industry
  • IOTR
  • NRXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • IOTR
  • NRXP Health Care
  • Exchange
  • IOTR NYSE
  • NRXP Nasdaq
  • Market Cap
  • IOTR 29.5M
  • NRXP 32.6M
  • IPO Year
  • IOTR 2025
  • NRXP N/A
  • Fundamental
  • Price
  • IOTR $0.48
  • NRXP $3.21
  • Analyst Decision
  • IOTR
  • NRXP Strong Buy
  • Analyst Count
  • IOTR 0
  • NRXP 4
  • Target Price
  • IOTR N/A
  • NRXP $28.50
  • AVG Volume (30 Days)
  • IOTR 327.6K
  • NRXP 202.4K
  • Earning Date
  • IOTR 01-01-0001
  • NRXP 08-13-2025
  • Dividend Yield
  • IOTR N/A
  • NRXP N/A
  • EPS Growth
  • IOTR N/A
  • NRXP N/A
  • EPS
  • IOTR N/A
  • NRXP N/A
  • Revenue
  • IOTR $10,478,550.00
  • NRXP N/A
  • Revenue This Year
  • IOTR N/A
  • NRXP N/A
  • Revenue Next Year
  • IOTR N/A
  • NRXP N/A
  • P/E Ratio
  • IOTR N/A
  • NRXP N/A
  • Revenue Growth
  • IOTR 22.27
  • NRXP N/A
  • 52 Week Low
  • IOTR $0.31
  • NRXP $1.10
  • 52 Week High
  • IOTR $5.98
  • NRXP $6.01
  • Technical
  • Relative Strength Index (RSI)
  • IOTR N/A
  • NRXP 51.07
  • Support Level
  • IOTR N/A
  • NRXP $3.12
  • Resistance Level
  • IOTR N/A
  • NRXP $3.53
  • Average True Range (ATR)
  • IOTR 0.00
  • NRXP 0.18
  • MACD
  • IOTR 0.00
  • NRXP -0.05
  • Stochastic Oscillator
  • IOTR 0.00
  • NRXP 41.82

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Share on Social Networks: